Karen Spindler, a partner in Goodwin's Technology & Life Sciences Group, advises life sciences companies and investors on a variety of intellectual property transactions. She represents biotech and pharmaceutical clients in transactions involving intellectual property assets and has considerable experience structuring collaboration, co-development, license and manufacturing agreements. She also counsels financial investors and operating companies on complex intellectual property issues arising in the context of corporate transactions, including mergers, stock and asset purchases, divestitures, royalty agreements, leveraged buyouts and financing transactions.

Ms. Spindler has been recognized as one of the nation’s leading patent and technology licensing lawyers by Euromoney Legal Media Group and Intellectual Asset Management.

Experience

ERFAHRUNG

工作经历

Ms. Spindler has advised Fortune 500 biopharmaceutical companies, semiconductor manufacturers and computer technology providers, as well as leading venture capital funds and private equity funds on a variety of intellectual property and licensing matters.

Representative Matters

REFERENZMANDATE

代表事项

Life Sciences Strategic Collaborations and M&A
  • Ginkgo Bioworks in its joint venture with Bayer focused on plant microbiome, with an initial investment of $100 million 
  • Foundation Medicine in the collaboration agreements forming part of its strategic transaction with Roche of a total value in excess of $1 billion
  • Royalty Pharma in its $3.3 billion purchase of Ivacaftor royalty rights from the Cystic Fibrosis Foundation
  • Royalty Pharma in its $415 million acquisition of royalty rights to alogliptin/trelagliptin products and Priligy® (dapoxetine) from Furiex Pharmaceuticals, Inc.
  • Blueprint Medicines in its strategic collaboration with Alexion Pharmaceuticals to advance kinase drug candidates in rare genetic diseases, with potential deal value of up to $265 million
  • Intellia Therapeutics in its exclusive collaboration with Novartis for CRISPR/Cas9 gene-editing technology for ex vivo therapeutic development, with potential deal value of up to $280 million plus royalties
  • Tetragenetics in its collaboration with MedImmune for a multi-target ion channel drug discovery program
  • Scholar Rock in its global research collaboration with Johnson & Johnson and Janssen Biotech for novel biologic therapeutics for the treatment of autoimmune diseases and cancer
  • Ocera Therapeutics in its sale to Mallinckrodt in a cash tender offer, plus contingent value right
  • Teva Pharmaceutical Industries in its $3.2 billion acquisition of Auspex Pharmaceuticals
  • Onyx Pharmaceuticals in its $10.4 billion sale to Amgen
  • Several biopharmaceutical clients on strategic licensing transactions involving early stage products
  • Clients on licensing foundational intellectual property assets from universities and other academic entities
Other Licensing and M&A/Private Equity
  • Enterprise server business division of Hitachi, Ltd. in connection with collaboration and supply agreements
  • Samsung Electronics Co., Ltd. in connection with patent acquisitions and complex strategic licensing transactions*
  • Private equity fund Thoma Bravo in its majority investment in SailPoint Technologies, and in connection with take-private and other leveraged buyout transactions (together with financing aspects of such transactions)
  • M&A clients on license compliance issues relating to open source software use in the product environment*

* Certain representative matters prior to joining Goodwin Procter

Professional Experience

Prior to joining Goodwin, Ms. Spindler was a partner in the Palo Alto and San Francisco offices of Kirkland & Ellis LLP.  Previously, she practiced at Skadden, Arps, Slate, Meagher & Flom LLP.

Recognition

Ms. Spindler has been named:

  • A "Life Sciences Star" by Euromoney Legal Media Group for licensing and collaboration expertise in the life sciences industry (every year since 2012)
  • One of the world's leading 1000 patent practitioners by Intellectual Asset Management (IAM) (every year since 2012)
  • One of the world's leading 300 IP strategists by Intellectual Asset Management (IAM) (every year since 2015)

In The News

MELDUNGEN

在新闻中

Credentials

WERDEGANG

专业资格

Education

J.D., 2002
Santa Clara University School of Law
(magna cum laude; Order of the Coif)
B.S., 1996
Stanford University
(with Honors)

Admissions

Bar

California
Get In Touch
KONTAKT
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
搜寻其他律师